Compare NAII & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAII | CTXR |
|---|---|---|
| Founded | 1980 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 19.8M |
| IPO Year | 1987 | N/A |
| Metric | NAII | CTXR |
|---|---|---|
| Price | $3.20 | $0.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 16.2K | ★ 1.3M |
| Earning Date | 02-13-2026 | 12-23-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $134,440,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $2.57 | $0.63 |
| 52 Week High | $4.40 | $5.95 |
| Indicator | NAII | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 56.17 | 35.44 |
| Support Level | $3.14 | $0.63 |
| Resistance Level | $3.46 | $1.18 |
| Average True Range (ATR) | 0.15 | 0.11 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 72.52 | 33.99 |
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.